In the TCGA AML cohort, we found that the predicted responders showed significantly higher expression levels of CD300A‐CD300LF but lower levels of CD300LG than non‐responders (Figure 8B), suggesting CD300 expression could be a good predictor for immunotherapy in AML. This evidence concerns the gene CD300LF and acute myeloid leukemia.